Status:
UNKNOWN
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
Lead Sponsor:
Max Healthcare Insititute Limited
Conditions:
COVID
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, an...
Detailed Description
This study aims to confirm the antivirus effectiveness of Ivermectin on coronavirus i.e COVID 19 then to explore its potential use in the combating to the COVID 19 pandemics. Enrollment of subject in...
Eligibility Criteria
Inclusion
- Subjects within age group between 18 to 75 years
- With either sex, male or female
- Confirmed case of COVID-19 at Max Hospitals.
Exclusion
- Patients who are critically sick
Key Trial Info
Start Date :
April 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 25 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04373824
Start Date
April 25 2020
End Date
July 25 2020
Last Update
May 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation)
New Delhi, National Capital Territory of Delhi, India, 110017